Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Prostate Cancer Therapeutics Market 2016 Share, Trend, Segmentation and Forecast to 2020

Wednesday, November 9, 2016 23:45
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Prostate Cancer Therapeutics Market Overview

The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future. 

Request a sample report @

Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer’s cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.

Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.

The report covers the following: 

1. Global Prostate Cancer – Hormonal Therapy Drugs Market

• Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists

1. Zytiga 
2. Gonax

• Luteinizing Hormone–Releasing Hormone (LHRH) Analogs

1. Lupron 
2. Zoladex 
3. Decapeptyl 
4. Eligard 
5. Vantas 
6. Leuplin

• Anti–Androgens 
1. Casodex 
2. Xtandi or MDV3100 
3. Xtandi US or MDV3100

2. Global Prostate Cancer Chemotherapy Drugs Market

1. Taxotere 
2. Jevtana

3. Global Prostate Cancer Immunotherapy Drugs Market

1. Provenge

4. Global Prostate Cancer Targeted Therapy Drugs Market

1. Xofigo or Alpharadin 

Data Sources 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Research team of industry experts. 

Primary sources include industry surveys and telephone interviews with industry experts. 

Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Complete report details @               

Key points in table of content

1. Executive Summary

2. Prostate Cancer – Overview 
    2.1 Prostate Cancer Introduction 
    2.2 Risk Factors 
      2.2.1 Age 
      2.2.2 Race 
      2.2.3 Family History/Genetics 
      2.2.4 Diet/Lifestyle Factors 
      2.2.5 Obesity 
      2.2.6 Infection/Inflammation of the Prostate Gland 
    2.3 Disease Symptoms 
    2.4 Diagnosis 
      2.4.1 Digital Rectal Exam (DRE) 
      2.4.2 Prostate Specific Antigen (PSA) Blood Test 
      2.4.3 Prostate Ultrasound and Biopsy 
      2.4.4 Bone Scan 
      2.4.5 CT Scan & MRI 
      2.4.6 PET & SPECT Scan 
      2.4.7 Lymph Node Biopsy 
      2.4.8 ProstaScint Scan 
    2.5 Stages of Prostate Cancer 
      2.5.1 Stage I 
      2.5.2 Stage II 
      2.5.3 Stage III 
      2.5.4 Stage IV

3. Global Prostate Cancer Drugs Market

4. Global Prostate Cancer Incidence

5. Global Prostate Cancer Drugs Market Share

6. Global Prostate Cancer – Hormonal Therapy Drugs Sales & Forecast to 2020 
    6.1 Luteinizing Hormone – Releasing Hormone (LHRH) Antagonists 
      6.1.1 Zytiga 
      6.1.2 Gonax / Firmagon 
    6.2 Luteinizing Hormone – Releasing Hormone (LHRH) Analogs 
      6.2.1 Lupron 
      6.2.2 Zoladex 
      6.2.3 Decapeptyl 
      6.2.4 Eligard 
      6.2.5 Vantas 
      6.2.6 Leuplin 
    6.3 Anti – Androgens 
      6.3.1 Casodex 
      6.3.2 Xtandi or MDV3100 
      6.3.3 Xtandi US or MDV3100

7. Global Prostate Cancer – Chemotherapy Drugs Market 
    7.1 Taxotere 
    7.2 Jevtana

8. Global Prostate Cancer – Immunotherapy Drugs Market 
    8.1 Provenge

9. Global Prostate Cancer – Targeted Therapy Drugs Market 
    9.1 Xofigo or Alpharadin

10. Global Prostate Cancer Market – Driving Factors 
    10.1 Introduction of Innovative Drugs 
    10.2 Advancement in Oncology Therapeutic Area 
    10.3 Development in Genomics & Proteomics

11. Global Prostate Cancer Market – Challenges 
    11.1 Costly Prostate Cancer Drugs 
    11.2 Adverse Events of Treatment 
    11.3 Low Success Rate for Oncology Drugs

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.